Alignment of Health Plan Reauthorization Criteria with Clinical Trial Endpoints for Neuromuscular Disease Therapies

Date: May 20, 2026
Journal: ISPOR 2026 (Poster Presentation)
Citation: Rucker JA, Lin Y, Figueroa CA, Chambers JD. Alignment of Health Plan Reauthorization Criteria with Clinical Trial Endpoints for Neuromuscular Disease Therapies. Poster presented at: ISPOR 2026. May 20, 2026; Philadelphia, PA.
Download Poster

More Publications

The Unintended Consequences of the Inflation Reduction Act on Biosimilar Market Incentives and Medicare Savings

View Publication

Trends in Specialty Drug Coverage Policy Complexity Among US Commercial Health Plans

View Publication

A Survey of HEOR Leaders in Pharma on the Changing US Policy Landscape

View Publication
View All Publications